SU673169A3 - Способ получени 5-м-толилоксиурацила - Google Patents
Способ получени 5-м-толилоксиурацилаInfo
- Publication number
- SU673169A3 SU673169A3 SU772502606A SU2502606A SU673169A3 SU 673169 A3 SU673169 A3 SU 673169A3 SU 772502606 A SU772502606 A SU 772502606A SU 2502606 A SU2502606 A SU 2502606A SU 673169 A3 SU673169 A3 SU 673169A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- tolyl
- oxyuracyl
- producing
- ethyl
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- -1 halo ester Chemical class 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- MRAFQBWAGNWURO-UHFFFAOYSA-N 5-(3-methylphenoxy)-1h-pyrimidine-2,4-dione Chemical compound CC1=CC=CC(OC=2C(NC(=O)NC=2)=O)=C1 MRAFQBWAGNWURO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZECTCSEONQIPP-UHFFFAOYSA-N 2-(3-methylphenoxy)acetic acid Chemical compound CC1=CC=CC(OCC(O)=O)=C1 VZECTCSEONQIPP-UHFFFAOYSA-N 0.000 description 1
- BTHLFOGNSHDSKT-UHFFFAOYSA-N 5-(3-methylphenoxy)-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CC=CC(OC=2C(NC(=S)NC=2)=O)=C1 BTHLFOGNSHDSKT-UHFFFAOYSA-N 0.000 description 1
- HCJMNOSIAGSZBM-UHFFFAOYSA-N 6-methylsalicylic acid Chemical compound CC1=CC=CC(O)=C1C(O)=O HCJMNOSIAGSZBM-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- NHYXMAKLBXBVEO-UHFFFAOYSA-N bromomethyl acetate Chemical group CC(=O)OCBr NHYXMAKLBXBVEO-UHFFFAOYSA-N 0.000 description 1
- SMJYMSAPPGLBAR-UHFFFAOYSA-N chloromethyl acetate Chemical group CC(=O)OCCl SMJYMSAPPGLBAR-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical class SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/706,123 US4080454A (en) | 1976-07-16 | 1976-07-16 | 5-M-Tolyloxyuracil, anti-ulcer agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU673169A3 true SU673169A3 (ru) | 1979-07-05 |
Family
ID=24836300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU772502606A SU673169A3 (ru) | 1976-07-16 | 1977-07-13 | Способ получени 5-м-толилоксиурацила |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US4080454A (enExample) |
| JP (1) | JPS5337673A (enExample) |
| AR (1) | AR213652A1 (enExample) |
| AT (1) | AT351561B (enExample) |
| BE (1) | BE856710A (enExample) |
| CA (1) | CA1061788A (enExample) |
| CH (1) | CH622512A5 (enExample) |
| CS (1) | CS212264B2 (enExample) |
| DD (1) | DD131556A5 (enExample) |
| DE (1) | DE2731736A1 (enExample) |
| DK (1) | DK139029B (enExample) |
| EG (1) | EG12762A (enExample) |
| ES (1) | ES460686A1 (enExample) |
| FI (1) | FI772183A7 (enExample) |
| FR (1) | FR2358399A1 (enExample) |
| GB (1) | GB1542178A (enExample) |
| GR (1) | GR68686B (enExample) |
| HU (1) | HU177713B (enExample) |
| IL (1) | IL52409A (enExample) |
| LU (1) | LU77764A1 (enExample) |
| NL (1) | NL7707729A (enExample) |
| NO (1) | NO772489L (enExample) |
| PH (1) | PH13190A (enExample) |
| PL (1) | PL103783B1 (enExample) |
| PT (1) | PT66808B (enExample) |
| SE (1) | SE421125B (enExample) |
| SU (1) | SU673169A3 (enExample) |
| YU (1) | YU171677A (enExample) |
| ZA (1) | ZA773927B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55158095A (en) * | 1979-05-25 | 1980-12-09 | Zenkosha Tokei Kk | Controller for washing machine |
| KR101452518B1 (ko) * | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| EP2120581A4 (en) * | 2007-02-20 | 2011-03-16 | Melior Pharmaceuticals I Inc | METHODS OF IDENTIFYING LYN KINASE ACTIVATORS |
| EP2180894A4 (en) * | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | METHOD OF ACTIVATING IRS-1 AND ACT |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2011150300A1 (en) * | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3609500B1 (en) | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
| CA3088178A1 (en) | 2018-02-21 | 2019-08-29 | Melior Pharmaceuticals I, Inc. | Treatment of liver diseases |
| WO2026125941A1 (en) | 2024-12-13 | 2026-06-18 | Biodexa Ltd. | Lyn kinase activators for use in treating fibrosis or diseases associated with fibrosis |
-
1976
- 1976-07-16 US US05/706,123 patent/US4080454A/en not_active Expired - Lifetime
-
1977
- 1977-06-27 CA CA281,423A patent/CA1061788A/en not_active Expired
- 1977-06-27 GR GR53819A patent/GR68686B/el unknown
- 1977-06-28 SE SE7707471A patent/SE421125B/xx unknown
- 1977-06-28 IL IL52409A patent/IL52409A/xx unknown
- 1977-06-29 ZA ZA00773927A patent/ZA773927B/xx unknown
- 1977-07-05 PH PH19953A patent/PH13190A/en unknown
- 1977-07-11 BE BE1008274A patent/BE856710A/xx unknown
- 1977-07-11 YU YU01716/77A patent/YU171677A/xx unknown
- 1977-07-11 FR FR7721285A patent/FR2358399A1/fr active Granted
- 1977-07-11 DE DE19772731736 patent/DE2731736A1/de not_active Withdrawn
- 1977-07-12 JP JP8349077A patent/JPS5337673A/ja active Granted
- 1977-07-12 NL NL7707729A patent/NL7707729A/xx not_active Application Discontinuation
- 1977-07-13 EG EG418/77A patent/EG12762A/xx active
- 1977-07-13 NO NO772489A patent/NO772489L/no unknown
- 1977-07-13 SU SU772502606A patent/SU673169A3/ru active
- 1977-07-13 DK DK318177AA patent/DK139029B/da unknown
- 1977-07-13 CH CH870277A patent/CH622512A5/fr not_active IP Right Cessation
- 1977-07-13 CS CS774680A patent/CS212264B2/cs unknown
- 1977-07-13 HU HU77PI583A patent/HU177713B/hu unknown
- 1977-07-13 FI FI772183A patent/FI772183A7/fi not_active Application Discontinuation
- 1977-07-13 ES ES460686A patent/ES460686A1/es not_active Expired
- 1977-07-14 AT AT509277A patent/AT351561B/de not_active IP Right Cessation
- 1977-07-14 DD DD7700200058A patent/DD131556A5/xx unknown
- 1977-07-14 GB GB7729667A patent/GB1542178A/en not_active Expired
- 1977-07-14 PT PT66808A patent/PT66808B/pt unknown
- 1977-07-14 LU LU77764A patent/LU77764A1/xx unknown
- 1977-07-14 PL PL1977199633A patent/PL103783B1/pl unknown
- 1977-07-14 AR AR268432A patent/AR213652A1/es active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20022205D0 (no) | Fremgangsmåte for fremstilling av maursyre | |
| KR870006193A (ko) | 항생물질 a 40926 만노실 아글리콘 및 그의 제조방법 | |
| GB799271A (en) | Production of intermediates for the synthesis of reserpine and allied compounds | |
| SE7705637L (sv) | Forfarande for framstellning av dibensoxepinderivat med terapeutisk verkan | |
| US2407920A (en) | Process of producing pentaerythritol | |
| SU430544A1 (ru) | Способ получения ^-алкоксиацетоуксусныхэфиров | |
| GB1056537A (en) | Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof | |
| US2358337A (en) | Vitamin intermediates and their preparation | |
| US2653955A (en) | Cortisone esters and process | |
| KR900018032A (ko) | 2,3-디클로로-5-아세틸피리딘의 제조방법 | |
| US3075997A (en) | 3, 5-dihydroxy-3-fluoro-methylpentanoic acid and the delta lactone thereof | |
| DK1252164T3 (da) | Fremgangsmåde til fremstilling af 6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-eddikesyre | |
| US2545092A (en) | Acylamido-hydroxy-propionaphthones | |
| NL7906109A (nl) | Werkwijze voor de bereiding van 4-(5)hydroxyl-5-(4) lager alkyl-imidazolen en hun zuur-additiezouten. | |
| SU507038A1 (ru) | Способ получени замещенных 4 @ -тиено-(2,3- @ ) (1,4)-бензотиазин-3-карбоновых кислот или их диалкиламиноалкиловых эфиров | |
| SU563415A1 (ru) | Способ получени 2-(1-оксиэтил)4,5,6,7-тетрагидроизо (или метаноизо) индолов | |
| KR950032069A (ko) | 디페놀릭애시드 t- 부톡시카르보닐메틸에스테르 유도체 및 그 제조방법 | |
| JPS5634671A (en) | Preparation of 5-substituted uracil | |
| US2741615A (en) | N-substituted dihydrodesoxynorcodeine compounds | |
| GB1389104A (en) | Process for preparing beta, delta-dioxoenanthaldehyde dialkyl acetals | |
| GB568512A (en) | Formylacetic ester | |
| US2741610A (en) | N-substituted desoxynorcodeine compounds | |
| JPS5824570A (ja) | ２，４−ジヒドロキシ−ピリミジンの製造法 | |
| US2459696A (en) | Process for the preparation of nornicotine | |
| US3036069A (en) | Acetoxylated 17alpha-carboxyethyl-17beta-hydroxyandrost-4-en-3-one lactones and intermediates |